Alzheimer’s disease (AD) and cancer both represent diseases that classically occur in older individuals. However, these diseases rarely occur i | Cancer ...
3D Printed Breast implants consisting of 200cc in volume of CollPlant's (CLGN) rhCollagen-based bioinks produced on a Stratasys' (SSYS) Origin® printer to be tested Technology innovation addresses a ...
More and more young adults seek psychological assessment with a diagnosis already in mind—or even one they have assigned to ...
The final histopathology and lab report supplements previous positive Company findings. The results of the study will support the Company’s IDE submission to the FDA to commence its human clinical ...
LOS ANGELES--(BUSINESS WIRE)--Laekna (2105.HK) announced today that the results of: i) the phase I SAD study of LAE102 (an ActRIIA-selective antibody) for the treatment of obesity; and ii) the ...
Alphamab Oncology (Stock Code: 9966.HK) announced that the results from a phase III clinical study for the treatment of HER2-positive gastric or gastroesophageal junction cancer (GC/GEJ) of ...
Activation of immune blood biomarkers from interferon gamma pathway distinguished long-term survivors (>=2 years) ...
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued to demonstrate the powerful disease-modifying effects of BB-301, with ...
REHOVOT, Israel & EDEN PRAIRIE, Minn., Aug. 19, 2024 /PRNewswire/ -- In a significant step in the advancement of regenerative medicine, CollPlant Biotechnologies (Nasdaq: CLGN) and Stratasys Ltd.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results